Gabelli Funds LLC Buys 72 Shares of Intuitive Surgical, Inc. (NASDAQ:ISRG)

Gabelli Funds LLC lifted its stake in Intuitive Surgical, Inc. (NASDAQ:ISRG) by 0.1% during the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 84,427 shares of the medical equipment provider’s stock after purchasing an additional 72 shares during the period. Gabelli Funds LLC’s holdings in Intuitive Surgical were worth $37,557,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also made changes to their positions in the stock. Vanguard Group Inc. boosted its position in shares of Intuitive Surgical by 1.6% in the 1st quarter. Vanguard Group Inc. now owns 30,868,620 shares of the medical equipment provider’s stock worth $12,319,358,000 after purchasing an additional 493,126 shares during the last quarter. Price T Rowe Associates Inc. MD boosted its position in shares of Intuitive Surgical by 1.6% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 16,973,266 shares of the medical equipment provider’s stock worth $5,726,102,000 after purchasing an additional 272,741 shares during the last quarter. Capital World Investors boosted its position in shares of Intuitive Surgical by 1.0% in the 1st quarter. Capital World Investors now owns 7,284,269 shares of the medical equipment provider’s stock worth $2,907,079,000 after purchasing an additional 73,634 shares during the last quarter. Edgewood Management LLC boosted its position in shares of Intuitive Surgical by 7.9% in the 4th quarter. Edgewood Management LLC now owns 5,131,066 shares of the medical equipment provider’s stock worth $1,731,016,000 after purchasing an additional 374,667 shares during the last quarter. Finally, Jennison Associates LLC boosted its position in shares of Intuitive Surgical by 4.6% in the 1st quarter. Jennison Associates LLC now owns 4,488,343 shares of the medical equipment provider’s stock worth $1,791,253,000 after purchasing an additional 198,483 shares during the last quarter. 83.64% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In other Intuitive Surgical news, EVP Myriam Curet sold 2,818 shares of the business’s stock in a transaction that occurred on Tuesday, July 23rd. The stock was sold at an average price of $458.13, for a total transaction of $1,291,010.34. Following the transaction, the executive vice president now owns 298 shares of the company’s stock, valued at $136,522.74. The sale was disclosed in a document filed with the SEC, which is available through this link. In other Intuitive Surgical news, EVP Myriam Curet sold 2,818 shares of the business’s stock in a transaction that occurred on Tuesday, July 23rd. The stock was sold at an average price of $458.13, for a total transaction of $1,291,010.34. Following the transaction, the executive vice president now owns 298 shares of the company’s stock, valued at $136,522.74. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, SVP Henry L. Charlton sold 40,243 shares of the business’s stock in a transaction that occurred on Friday, August 23rd. The stock was sold at an average price of $486.84, for a total value of $19,591,902.12. Following the transaction, the senior vice president now directly owns 3,001 shares in the company, valued at approximately $1,461,006.84. The disclosure for this sale can be found here. Insiders have sold a total of 53,120 shares of company stock valued at $25,528,753 over the last 90 days. 0.90% of the stock is currently owned by insiders.

Analysts Set New Price Targets

ISRG has been the topic of several recent analyst reports. The Goldman Sachs Group initiated coverage on Intuitive Surgical in a report on Thursday, May 30th. They set a “buy” rating and a $500.00 target price on the stock. Truist Financial lifted their target price on Intuitive Surgical from $450.00 to $515.00 and gave the stock a “buy” rating in a report on Tuesday, July 16th. Citigroup lifted their target price on Intuitive Surgical from $512.00 to $560.00 and gave the stock a “buy” rating in a report on Thursday, August 22nd. Robert W. Baird lifted their target price on Intuitive Surgical from $487.00 to $503.00 and gave the stock an “outperform” rating in a report on Friday, July 19th. Finally, BTIG Research lifted their target price on Intuitive Surgical from $469.00 to $494.00 and gave the stock a “buy” rating in a report on Wednesday, August 28th. Six investment analysts have rated the stock with a hold rating and fifteen have given a buy rating to the company. According to data from MarketBeat.com, Intuitive Surgical currently has an average rating of “Moderate Buy” and an average target price of $446.45.

Intuitive Surgical Stock Performance

NASDAQ:ISRG opened at $486.20 on Friday. The stock’s 50-day simple moving average is $468.01 and its 200 day simple moving average is $425.12. The company has a market cap of $172.46 billion, a P/E ratio of 87.76, a P/E/G ratio of 5.41 and a beta of 1.39. Intuitive Surgical, Inc. has a 52-week low of $254.85 and a 52-week high of $496.18.

Intuitive Surgical (NASDAQ:ISRG) last released its earnings results on Thursday, July 18th. The medical equipment provider reported $1.78 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.54 by $0.24. The business had revenue of $2.01 billion for the quarter, compared to the consensus estimate of $1.97 billion. Intuitive Surgical had a return on equity of 13.04% and a net margin of 27.65%. Intuitive Surgical’s quarterly revenue was up 14.5% on a year-over-year basis. During the same quarter in the previous year, the business earned $1.18 earnings per share. As a group, equities analysts predict that Intuitive Surgical, Inc. will post 5.22 earnings per share for the current fiscal year.

Intuitive Surgical Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.